

For pregnant women with Rh (D) negative blood group

Rh (D) immunoglobulin Material Fax Request Sheet

To order support information on Rh (D) immunoglobulin
please fill in your details below and fax to:
National Mailing & Marketing
Fax: (02) 6260 2770
Email: nmm@nationalmailing.com.au

Contact Details:

Name: _____

Role: O&G Haematologist Pathologist GP Nurse Midwife
 Scientist Other (please specify) _____

Department: _____

Organisation: _____

Address: _____

State: _____ Postcode: _____

Phone: (_____) _____ Date: _____

E-Mail: _____

Privacy Policy:

National Mailing & Marketing adhere to Section 79 of the Commonwealth Crimes Act 1914 at all times. NMM also complies with the principles and obligations included in the *Privacy Act 1998* and the *Privacy Amendment (Private Sector) Act 2000*. Your personal information will not be used for any other purpose.

Item description: (please tick)

Order Quantity:

- | | |
|---|-------|
| <input type="checkbox"/> "You and Your Baby: Important information for Rh (D) negative women" (6 page booklet)* | _____ |
| <input type="checkbox"/> "Important Information for Rh (D) Negative Women: Prevention of Haemolytic Disease of the Newborn".
This booklet is for women who experience early pregnancy loss (6 page booklet)* | _____ |
| <input type="checkbox"/> Guidelines for the use of Rh (D) immunoglobulin wall poster (500mm x 340mm)* | _____ |
| <input type="checkbox"/> Rh (D) Immunoglobulin Material Fax Request Sheet | _____ |
| <input type="checkbox"/> Approved Product Information for Rh (D) Immunoglobulin-VF | _____ |
| <input type="checkbox"/> Consumer Medicine Information for Rh (D) Immunoglobulin-VF | _____ |
| <input type="checkbox"/> Frequently Asked Questions about the use of Rh (D) immunoglobulin | _____ |

*Can also be downloaded in pdf format from www.transfusion.com.au/RhD

For further technical support, please contact ARCBS in your capital city or CSL Biotherapies.

This document was prepared January 2006, revised February 2010.

CSL Limited, Biotherapies Division, 189 - 209 Camp Road, Broadmeadows, Victoria, Australia 3047. ABN: 99 051 588 348
For Medical/Technical Inquiries: Ph: 1800 067 140 For Customer Service Inquiries: Ph: 1800 063 892
E-mail: customerservice.plasmaproducts@csl.com.au Internet: www.csl.com.au ® Registered trade mark of CSL Limited.

or
Australian Red Cross Blood Service, ABN: 50 169 561 394 Contact the local Transfusion Medicine Specialist in your capital city.
Email: clinicalinfo@arcbs.redcross.org.au Internet: www.transfusion.com.au

CSL Biotherapies 1362

For best practice
the National
Blood Authority
(NBA) 2003
Guidelines¹
recommend:

- Rh (D) immunoglobulin should be administered as soon as possible after the sensitising event, but always within 72 hrs for successful immunoprophylaxis.^{1,2}

- If Rh (D) immunoglobulin has not been administered within 72 hrs, a dose offered within 10 days may provide protection.¹

- To avoid wastage, Rh (D) immunoglobulin should not be given to women with preformed anti-D antibodies, except where the preformed anti-D is due to the antenatal administration of Rh (D) immunoglobulin.¹

- Original studies have shown that 100 IU of Rh (D) immunoglobulin is sufficient to protect against a Fetomaternal Haemorrhage (FMH) of 1.0 mL of fetal red cells (2 mL whole blood).¹ For example, Rh (D) immunoglobulin 625 IU is sufficient to protect against a FMH of 6 mL of fetal red cells (12 mL of whole blood).

- Quantify the magnitude of the FMH following a sensitising event (including delivery) to ensure an adequate dose of Rh (D) immunoglobulin is offered, as more than 1 dose may be required.¹

- Tests to assess the volume of FMH include, but are not limited to, the Kleihauer acid elution test and flow cytometry.¹

Guidelines for the use of Rh (D) immunoglobulin

in pregnant women with Rh (D) negative blood group, and no pre-existing anti-D antibodies¹

For each sensitising event eg. normal delivery, miscarriage, termination of pregnancy, ectopic pregnancy, chorionic villus sampling, amniocentesis, abdominal trauma, antepartum haemorrhage, or external cephalic version. ^{1,2}			
Week 1 to Week 12 (first trimester)		Beyond Week 12 (second & third trimester)	Postpartum
Rh (D) Immunoglobulin-VF (Single pregnancy)	Rh (D) Immunoglobulin-VF (Multiple pregnancy eg. twins)	Rh (D) Immunoglobulin-VF	Rh (D) Immunoglobulin-VF
250 IU	625 IU	625 IU	625 IU

Routine prophylaxis is recommended for all Rh (D) negative pregnant women.	Rh (D) Immunoglobulin-VF
Administer at Week 28 and Week 34	625 IU The doses at 28 & 34 weeks are given in ADDITION to any doses given for sensitising events.

Rh (D) Immunoglobulin-VF is administered by intramuscular injection only.²

In some circumstances, access to an intravenous Rh (D) immunoglobulin preparation may be warranted. A quantity of intravenous Rh (D) immunoglobulin will be available for this purpose. Contact ARCBS for further information.

The batch number of every vial of human immunoglobulin administered must be recorded in the patient's medical history and in accordance with other legal statutory requirements.²

References:

1. National Blood Authority Guidelines on the prophylactic use of Rh(D) immunoglobulin (anti-D) in obstetrics. June 2003.
2. Rh(D) Immunoglobulin-VF Approved Product Information amended 07 December 2007.
3. Sebring ES & Polesky HF. Transfusion 1990;30(4):344-357
4. Zipursky A. Clinical Obstetrics & Gynecology 1977;20:759-772
5. Australian & New Zealand Society of Blood Transfusion (ANZSBT). Topics in Transfusion Medicine 2003 May; Vol10(1)
6. Crowther CA, Middleton P. Anti-D administration in pregnancy for preventing Rhesus alloimmunisation. Cochrane Database of Systematic Reviews 1999; Issue 2. Art. No.:CD000020. DOI:10.1002/14651858.CD000020.

- The majority of fetal bleeds are less than 5 mL of red blood cells
 - in about 74% of cases, FMH is < 0.05 mL whole blood mL^{3,4}
 - in about 8% of cases, FMH is > 0.4 mL whole blood^{3,4}
 - in about 4% of cases, FMH is > 1 mL whole blood^{3,4}
 - in 0.3-0.6% of cases, FMH is ≥ 30 mL^{3,4}

- Approximately 15% of pregnant women will be Rh (D) negative, and their babies (if Rh (D) positive) may be at risk of developing Haemolytic Disease of the Newborn (HDN) due to Rh (D) incompatibility.⁵

- Antibody formation occurs during pregnancy in about 1-1.5% of Rh (D) negative women carrying a Rh (D) positive infant, despite use of postnatal prophylaxis. The rate of antibody formation can be reduced to 0.2% or less by the administration of Rh (D) immunoglobulin during pregnancy, at 28 weeks and 34 weeks (antenatal prophylaxis), as well as after delivery.⁴⁻⁶

PBS Information: This product is not listed on the PBS. This product is funded under arrangements implemented by the National Blood Authority. Please refer to the National Blood Authority for details.

The Medicines Australia Code of Conduct defines standards for the content of materials produced, and the conduct of promotional activities undertaken, by pharmaceutical companies within Australia. As a member of Medicines Australia, CSL Biotherapies willingly complies with the Medicines Australia Code of Conduct (www.medicinesaustralia.com.au).

Before prescribing, please review Product Information available on request from CSL Biotherapies

Minimum Product Information

Rh (D) Immunoglobulin – VF (Human Anti-D Rh₀ Immunoglobulin)

Indications: The prevention of Rh sensitisation in Rh(D) negative females at or below child bearing age. **Contraindications:** Individuals who are Rh(D) positive or D^u positive; Rh negative and D^u negative individuals previously sensitised to the Rh(D) antigen; individuals with IgA deficiency; individuals with coagulation disorders that would contraindicate intramuscular injections. **Precautions:** Rh(D) IMMUNOGLOBULIN-VF must not be administered intravenously. It should not be given to Rh(D) positive infants. Rh(D) IMMUNOGLOBULIN-VF should be given with caution to patients with a history of prior systemic allergic reactions following the administration of human immunoglobulin preparations. Rh(D) IMMUNOGLOBULIN-VF is made from human plasma. Products made from human plasma may contain infectious agents, such as viruses and theoretically Creutzfeldt-Jakob Disease (CJD) agents, that can cause disease. The risk that such products will transmit an infectious agent has been reduced by screening plasma donors, and by dedicated virus removal and inactivation procedures included in the manufacturing process. Despite these measures, such products may still potentially transmit disease. Vaccination for patients in receipt of medicinal products from human plasma should be considered where appropriate. **Interactions:** Rh(D) IMMUNOGLOBULIN-VF may interfere with serological testing and may affect the response to live, attenuated vaccines. For all precautions and interactions review approved PI. **Adverse Effects:** Local tenderness, erythema and stiffness at the injection site. For less common reactions review approved PI. **Dosage & Administration:** 250 IU after sensitising events during the first trimester of pregnancy; this should be increased to 625 IU for twin and multiple pregnancies. 625 IU after sensitising events beyond the first trimester. For mismatched transfusions or large foeto-maternal bleeds 100 IU Rh(D) IMMUNOGLOBULIN-VF should be administered for each 1.0 mL of Rh(D) positive red cells. The dose should be given as early as possible and within 72 hours of exposure. Rh(D) IMMUNOGLOBULIN-VF must be given by intramuscular injection. Contains no antimicrobial agent, use immediately after opening. Based on Rh(D) IMMUNOGLOBULIN-VF Approved Product Information amended 7 December 2007.